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Abstract 
Background 
With increased governmental interest in value assessment of technologies and where medical 
device manufacturers are finding it increasingly necessary to become more familiar with 
economic evaluation methods, the study sought to explore the levels of health economics 
(HE) knowledge within small and medium-sized enterprises (SMEs) and to scope strategies 
they employ to demonstrate the value of their products to purchasers. 
Methods 
A short questionnaire was completed by participants attending one of five workshops on 
product development in the medical device sector that took place in England between 2007 
and 2011. From all responses obtained, a large proportion of participants were based in SMEs 
(N = 43), and these responses were used for the analysis. Statistical analysis using non-
parametric tests was performed on questions with approximately interval scales. Qualitative 
data from participant responses were analysed to reveal emerging themes. 
Results 
The questionnaire results revealed that 60 % of SME participants (mostly company directors 
or managers, including product or project managers) rated themselves as having low or no 
knowledge of health economics prior to the workshops but the rest professed at least medium 
knowledge. Clinical trials and cost analyses or cost-effectiveness studies were the most 
highly cited means by which SMEs aim to demonstrate value of products to purchasers. 
Purchasers were perceived to place most importance on factors of safety, expert opinion, 
cost-effectiveness and price. However many companies did not utilise formal decision-
making tools to prioritise these factors. There was no significant dependence of the use of 
decision-making tools in general with respect to professed knowledge of health economics 
methods. SMEs did not state a preference for any particular aspect of potential value when 
deciding whether to develop a product. A majority of SMEs stated they would use a health 
economics tool. Research and development teams or marketing and sales departments would 
most likely use one. 
Conclusion 
This study points to the need for further research into the education requirements of SMEs in 
the area of Health Technology Assessment and also for investigation into how SMEs engage 
with existing HTA processes as required by assessors such as NICE. 
Background 
There has been an increasing focus on economics to answer questions around efficiency and 
value for money in healthcare [1]. For the medical device sector, this focus has permeated 
through an increasing reliance on health technology assessments (HTAs) to ensure that the 
introduction of a new drug, medical device, or procedure is cost effective in line with static or 
shrinking health budgets in Europe and elsewhere [2]. For the medical device sector, HTA is 
seen as providing a means of bridging scientific evidence, the judgment of health 
professionals, the views of patients and the general public, and the needs of policymakers [3]. 
From a policy perspective, the potential value of economic evaluation to public health policy 
decisions, particularly at the early stages of development, includes supplementation of 
monitoring and assessment of innovations in horizon scanning and HTA activities, the 
control of technology diffusion by informing coverage and reimbursement decisions, and the 
direct public promotion of healthcare technologies, leading to increased efficiency [4]. In line 
with this subscription to HTA methodology, there has been an increase in demand for 
economic evidence and its evaluation from purchasers and regulators. 
In the UK, one of the outcomes of the Healthcare Industries Task Force initiative [5], 
comprising British government, health professionals, and representatives from the medical 
technology industry, was to bring health economics (HE) considerations into purchasing 
guidance by the creation, in 2005, of the Centre for Evidence-based Purchasing (CEP) out of 
the more technically oriented Device Evaluation Service (DES). More recently the Medical 
Technologies Evaluation Programme (MTEP) of the National Institute of Health and Clinical 
Excellence (NICE) has taken over the remit of CEP with the aim of helping the National 
Health Service (NHS) in England and Wales adopt efficient and cost-effective medical 
devices and diagnostics more rapidly and consistently [6]. This technology evaluation 
programme demands that manufacturers provide their own evidence of economic value from 
existing literature or from de novo economic models in addition to the usual clinical 
evidence. The MTEP programme requires at least a cost-consequence analysis to be 
conducted where cost and clinical benefits are tabulated side by side so that decision makers 
can make judgements about costs associated with the benefits. However, cost-effectiveness is 
explicitly absent from NICE‟s existing Interventional Procedures Programme where device-
related procedures have been typically submitted for evaluation before the existence of the 
MTEP, so this is a considerable change for manufacturers of medical devices. Furthermore it 
has also meant changes for the evaluation organisations involved, several of which have 
provided services throughout the transition from DES to NICE. 
The NHS has also been striving to improve its level of innovativeness through the efforts of 
the National Innovation Centre, the National Technology Adoption Centre and through 
programmes such as QIPP (Quality, Innovation, Productivity and Prevention). This has 
resulted in the widening of interest in HE amongst healthcare organisations more generally. 
In the USA, comparative effectiveness research focuses on the generation and synthesis of 
clinical evidence to compare the benefits and harms of alternative methods to address a 
clinical condition or improve the delivery of care. Its introduction and applicability to “real 
world” settings raises the question of the need for wider understanding of HE methods for 
those who may wish to articulate the cost impact of selected treatments on health systems, 
and for companies that are providing products associated with those treatments [7]. 
Whilst the demand for economic evaluation in medical device development is growing, there 
has also been thinking around how to integrate findings from HE work into practice. It has 
been acknowledged that there are outstanding problems around the incorporation of HE 
methods into the medical device sector which has inhibited the use of more established 
methods common in the evaluation of pharmaceutical products. For example, the nature of 
ongoing product modifications that are experienced by devices during development means 
that there is unlikely to be a „steady-state‟ period where a device could be evaluated in a 
traditional setting such as a randomised controlled trial [8]. Further to this, a new therapy 
involving a device may have a wider financial implication for a healthcare provider 
organisation that is more difficult to forecast [9]. From the provider perspective, an 
interactive process in which clinical and economic estimates are used alongside emerging 
evidence from actual use has been highlighted as one means of addressing the issue [10]. 
Even so, there is ongoing discussion about the construction of such estimates (e.g. should the 
public or experts be consulted in the construction and elicitation of quality of life estimates) 
[11]. These details may not be so much of a concern if companies are able to apply “rough 
and ready” methods at very early stages of development [12] and if assessors are 
accommodating to such practices [13]. While research explores the need to strengthen 
modelling for devices and plans new ways to incorporate emerging evidence into analyses 
[8], there is still a need to establish how manufacturers and the medical device industry 
incorporate economic evaluations of new and existing products to articulate their value to 
purchasers and regulators. 
In the UK, the main government agency for funding research and training in engineering and 
the physical sciences, the Engineering and Physical Sciences Research Council (EPSRC), is 
supporting multidisciplinary applied research in medical device evaluation. This involves 
knowledge transfer of HE methods and tools to the healthcare technologies industry. In a 
short, exploratory study conducted by the authors, linked to a series of workshops for the 
medical device industry, participants completed a questionnaire to provide insight into the 
self-reported levels of HE knowledge (in terms of assessing whether procedural knowledge of 
health economics was rated as high or low), strategies currently used by SMEs to assess and 
articulate the value of new technology, and factors perceived by SMEs to be of importance to 
purchasers in the context of appraising technology. The insight sought from this research is 
current practices of SMEs and how this can be used to inform wider efforts in the education 
available to industry. Whilst SMEs can draw on health economics consultancy and other 
providers of such services, it is the in-house practices that are examined in this paper. 
Method 
This research adopted an exploratory approach to investigate HE knowledge of participants 
attending workshops for the medical device sector on product development, and identify 
factors that they perceived as important to purchasers. This was achieved through the analysis 
of participant responses to paper-based questionnaires that were administered following a 
workshop. As one part of a university-led research programme in evaluation methods and 
tools for medical device innovation, the authors hosted a range of half-day workshop events, 
lasting around four hours each, between 2007 and 2011. The workshops were free to attend, 
and were designed to introduce medical device manufacturers to tools for use in product 
development. The tools included a user requirements guide to support user testing and 
requirements gathering [14], and a spreadsheet tool for early economic assessment of medical 
devices [15], which were introduced and discussed within the context of clinical case studies. 
Industry views about involving users during development have been reported on elsewhere 
[16]. 
In total, 12 workshops took place, provided to members of industry networks, and trade 
associations. The events were hosted by the Association of British Healthcare Industries trade 
association, and four of the regional industry network partnerships (Medilink East Midlands, 
Medilink West Midlands, Yorkshire & Humberside Medilink and the South East Health 
Technology Alliance). The marketing for all events was focused on attracting participants 
from small and medium-sized enterprises (SMEs) and innovators that were looking to focus 
on uptake of their products by the NHS. 
Due to resource and time constraints, data was gathered at five of the workshops, which 
comprises the data presented in this paper. Data was captured from workshops based in the 
East Midlands, Yorkshire and Humber and South East of England, although participants who 
attended the workshops were based in companies outside of the geographical boundaries. 
Data from two workshops hosted by Medilink East Midlands were included in this paper. The 
questionnaires were provided to the participants at the end of the workshop session, so that 
responses relating to HE knowledge prior to the workshop could be informed following 
discussion of the topic. The questionnaires were administered by a researcher not involved in 
the delivery of the content for the workshop. The questionnaires outlined that information 
provided was to be used for academic research into the needs of industry and adopters of 
innovations within the NHS, was confidential, and that reported findings from the research 
will not refer to named organisations. 
The questionnaire contained six sections: i) description of participants‟ organisation and their 
role within it; ii) self-rating of their procedural knowledge of HE prior to the workshop (using 
5-point scale from „none‟ to „expert); iii) participant identification of any formal decision-
making tools that are used within their organisation to support product development (e.g., 
strategic and financial valuation of projects, weighting and scoring of products and product 
criteria) iv) participant rating of the importance of six decision-making priorities when 
initiating medical device development, using 5-point scale from „very important‟ to „not 
important‟ (anticipated profit margin, market competition, enthusiasm of customer for a 
device, purchasers opinion, expert opinion, uniqueness of the technology); v) participant 
rating of how important they thought each of seven factors were to purchasers when assessing 
a product during procurement, using 5-point scale from „very important‟ to „not important‟ 
(device price, cost effectiveness, expert opinion, patient group opinion, safety of the product, 
company reputation, environmental impact); vi) participants description of how they would 
aim to demonstrate the value of medical products to the NHS or other healthcare purchasers 
(e.g., clinical trial, key opinion leaders, cost-effectiveness calculation); vii) whether 
participants envisaged that a spreadsheet tool for early economic assessment of medical 
devices could be utilised by their company (responding with the options „yes‟, „maybe‟, or 
„no‟), and were asked to list who would be likely to use it. The factors included in questions 
around decision-making priorities and purchaser decisions during procurement were 
generated through discussions within the research team, drawing on expertise in the 
development and purchasing of medical devices. Qualitative data from participant responses 
were analysed to reveal emerging themes, presented as frequencies or indicative extracts of 
respondent text. Where appropriate, responses were compared against five levels of HE 
knowledge as the independent variable. Statistical analysis using non-parametric tests was 
performed on questions with approximately interval scales. Where statistical analysis was 
required for responses, IBM® SPSS® software was used. 
Results 
Organisations and role of participants 
Of the total number of participants who attended the five workshops (N = 69), 62 % were 
from SMEs (N = 43) (see Table 1). The remaining participants were from larger companies, 
universities or health providers. Although all participants from SMEs completed a post-event 
questionnaire, responses were not provided by participants for all of the questions. The 
majority of participants from SMEs held the role of managing director or director in the 
company in which they were based, with the role of director covering responsibilities across a 
range of activities, including marketing, new product development, and commercial roles. 
Table 1 Breakdown of the job roles of workshop participants attending the workshops 
Job role Number (%) 
Director 17 (39.5 %) 
Managing Director 16 (37.2 %) 
Manager 2 (4.7 %) 
Product Manager 2 (4.7 %) 
Senior Project Manager 1 (2.3 %) 
Company Secretary 1 (2.3 %) 
Senior Partner 1 (2.3 %) 
Consultant 1 (2.3 %) 
Not Defined 2 (4.7 %) 
Health economics knowledge 
Of the participants from SMEs, 23 % of respondents reported having no, or almost no, 
knowledge of HE, 37 % reported a response of low HE knowledge, 33 % medium, 5 % high 
and 2 % expert (Figure 1). 
Figure 1 Knowledge of health economics amongst workshop participants (N = 43) 
Use of formal decision-making tools within participant companies 
When asked to identify any formal decision-making tools that are used within their 
organisation, 42 % of respondents (N = 40) said that they were using at least one form of tool 
in their business. Amongst the respondents, stage-gate methods, technology roadmaps and 
HE were mentioned as formal methods and alongside responses that identified the use of 
formal methods without specifying exact methods. Amid the reported HE methods used, 
Monte Carlo sensitivity simulations (a financial planning approach that analyses multiple 
projections using a range of possible return rates), basic HE models and use of Quality-
adjusted Life Years (QALY) (a metric that takes into account both the quantity and quality of 
life generated by healthcare interventions and is the arithmetic product of life expectancy and 
a measure of the quality of the remaining life-years [17]) were highlighted. Quantitative 
market research methods were also described as formal by some respondents. Decision 
methods described as informal by participants included prior experience, boardroom 
decisions and decisions made on criteria of market analysis/user demand and practical means 
of delivery, also including assessment of intellectual property protection. 
Table 2 shows that the use of formal decision-making tools was greater for those participants 
reporting medium, high, and expert HE knowledge, with greater proportions of those 
reporting low to none HE knowledge also being non-users of formal decision-making tools. 
The relationship between this variables was assessed, but no significant relationship was 
found (τ = −0.138, p ≥ 0.05). 
Table 2 Knowledge of Health Economics vs. Use of Formal Decision-Making Tools 
Knowledge of Health Economic Use of Formal Decision Making Tools (N = 40)  
 Yes No 
None 4 (44 %) 5 (56 %) 
Low 4 (27 %) 11 (73 %) 
Medium 7 (54 %) 6 (46 %) 
High 1 (50 %) 1 (50 %) 
Expert 1 (100 %) 0 (0 %) 
Decision-making priorities 
When probing companies‟ motivating factors for developing a new product using six factors 
(anticipated profit margin, market competition, enthusiasm of the customer for the device, 
purchaser opinion, expert opinion and uniqueness and readiness of the product) a Friedman 
test was used to analyse variance in the participant responses (N = 32) by ranks. However, the 
analysis revealed no significant differences in the ranking of these six factors (χ2 (5) = 7.00, 
p ≥ 0.05). 
Participant rating of factors perceived to be of importance to purchasers 
To examine the participants‟ ratings of factors perceived to be of importance to purchasers 
when assessing a product during procurement (N = 39), responses were ranked using the 
Friedman test which highlighted an overall statistically significant difference between the 
mean ranks of the related groups (χ2 (6) = 88.26, p < 0.05). Table 3 displays the average ranks 
of the different categories according to their perceived importance to purchasers. 
Table 3 Factors of importance to purchasers, as rated by the delegates 
Category Rank 
Safety of the Product 2.89 
Expert Opinion 2.97 
Cost Effectiveness 3.12 
Device Price 3.32 
Company/Brand Reputation 4.51 
Patient Group Opinion 5.32 
Environmental Impact of a Product 5.85 
From these tests we were able to rank the six factors. Safety of the product, Expert opinion, 
Cost-effectiveness and Device price were found to be similarly ranked (mean rank between 
2.89 and 3.32) with no statistical difference between these factors. This was followed by 
Company/brand reputation and Patient group opinion which were both ranked significantly 
lower than all of the top four factors, but not significantly different from each other (ranking 
4.51 and 5.32 respectively). Lastly, Environmental impact had the lowest rank that was 
significantly lower than all other factors (mean rank 5.85). 
Participants’ description of how they aim to demonstrate the value of medical 
products to the NHS or other healthcare purchasers 
Workshop participants were asked to put in words how they would demonstrate value to 
purchasers. Table 4 documents explicit mention of methods used by the participants (N = 43), 
which were accompanied by more general references to evidence-based medicine, cost-
benefit analysis to healthcare providers and patients, and statement of benefits. The responses 
documented in Table 4 were coded from qualitative responses, with a varied number of 
responses provided by individual participants. 
Table 4 Methods currently used by delegates to demonstrate value to purchasers 
Methods used for demonstrating value Number of delegates 
Clinical trials (external and internal) 11 
Cost analysis and cost-effectiveness studies 10 
Outcomes Survey 4 
Demonstrate public and patient benefit 4 
Comparative studies 2 
Demonstrate benefits to user 2 
Opinion leader support 2 
All factors listed in the questionnaire 2 
Demonstrate product quality 1 
Demonstrate benefit to healthcare provider 1 
Peer-review publications 1 
Seminars / demonstrations 1 
To provide more insight into the descriptions provided by participants about how their 
company aims to demonstrate the value of medical products to purchasers, Table 5 outlines 
the exact responses of a selection of participants. 
Table 5 Participant responses about how their company aims to demonstrate the value 
of medical products to purchasers 
Statement Role in 
company 
HE 
knowledge 
“Comparative studies by experts” Director Low 
“…through products effectiveness, values, and how it can help 
improve users and patients life” 
Product 
Manager 
Low 
“Show the data on public health impact” Consultant Low 
“Seminars, demos” Director Medium 
“By demonstrating product quality” Senior Partner Medium 
“Business model based on PSSRU figures, clinical benefits, 
peers review formal publications” 
Director High 
It is apparent from reviewing the comments that there is diversity in the approaches applied 
by SMEs and no clear consensus was evident in the reporting of methods used to demonstrate 
the value of their medical products is present. 
The last question on the questionnaire asked participants whether they would consider using a 
HE spreadsheet tool in their company and who would be likely to use it. From the responses 
gathered (N = 39), 67 % of participants indicated that they would be likely to use such a tool, 
26 % stated maybe, and 7 % said that they would not use such a tool. For those participants 
who identified that they would be likely to use such a tool, it was highlighted that there would 
be scope to apply the tool in research and development teams, marketing and sales 
departments, or both within their companies. 
Discussion 
Amongst participants from SMEs attending training workshops tools for use in product 
development, HE was perceived as of importance to purchasers, and is entering into decision-
making processes by SMEs in the medical devices industry. Prior knowledge of HE was such 
that 2 in 5 of the participants already had at least medium knowledge. Cost-effectiveness was 
ranked by SMEs to be amongst the top factors influencing purchasers, and 92 % of 
respondents said that their company would use or might use a HE tool. At the same time, less 
than half of the companies reported using formal methods of decision support during product 
development. In terms of demonstrating the value of a product, clinical trials appear to 
dominate as the main way of doing this, alongside cost-effectiveness which was mentioned 
by almost 1 in 6 participants in those applying formal methods. 
The findings of this paper suggest that, for those participants from SMEs who attended the 
workshops, there is an awareness of the increasing use of HE by purchasers in decision 
making. However, the varying levels of HE knowledge reported by participants from SMEs, 
and the lack of HE in decision making during product development suggests that attention 
may need to be given to education needs, and tools to support the application of HE. There is 
currently no research that examines the most effective means of educating those from 
industry about HE and the wider coverage of HTA, so this is also an area for future research. 
Taking a global perspective in their report on HTA assessment of medical devices, the World 
Health Organisation [18] outline that disseminating knowledge and skills in HTA should be 
based on a progressive strategy. The suggested first stage is the identification of individuals 
with a capacity for accessing and understanding HTAs, and then making these individuals the 
“focal points” of HTA and scientific evidence of effectiveness of healthcare interventions. 
The “focal points” could be located in a national research organisation, government, a 
university or other non-profit agencies concerned with advancing the use of HTA for good 
governance in policy and decision making. Their role would be to facilitate and mobilise 
knowledge around HTA, using such methods as organising or facilitating meetings, providing 
presentations and conducting workshops. The WHO report draws on research from Romania 
[19] in which it is pointed out that success in implementing a HTA presence in a country 
setting depends on factors such as local political, economic, and educational support. The 
multidisciplinary and interdisciplinary nature of HTA sees HE amidst its array of components 
and, as such, how it is taught to and used by manufacturers feeds into the wider 
implementation of HTA. With well-established HTA bodies in the UK, it is a useful testing 
ground to understand how best manufacturers and developers of medical technology can 
adopt and implement HE within an environment in which there are increasing calls for its 
use. The progressive strategy outlined by the WHO may provide an opportunity to assess the 
agenda for increasing knowledge around HE within the context of HTA, alongside providing 
understanding on how best to disseminate knowledge to support HTA development more 
widely. 
In the UK, processes such as the NICE Medical Technologies Evaluation Programme 
(MTEP) do now require the formalised use of economic evaluation methods such that 
submissions by industry are expected to perform at least a cost-consequence analysis. 
Although process and methods guides are provided for those submitting technologies to this 
programme, the indication in this research that some companies would use a spreadsheet tool 
for early economic evaluation, in particular those who see scope for its use in research and 
development, indicates that there may be scope for policy makers to engage with industry 
through the generation of spreadsheet tools, such as those that are generated by NICE as 
costing templates as part of implementation support. 
Whilst this research has generated an initial insight into the knowledge and awareness of HE 
use within HTA for the medical device sector, it is acknowledged that the sample size was 
inadequate to extrapolate out to represent SMEs throughout the whole UK medical device 
sector. Further research is required to identify the extent of HE knowledge within SMEs and 
to develop methods to support the education and implementation of HE within the HTA 
landscape for medical devices in the UK. As a starting point, research has shown that those 
developing innovative medical devices struggle to express the value of their work because 
they only engage with HE at the later stages of development [20]. 
Any strategy around improving knowledge of HE within the medical device industry should 
act on research showing the benefits of its inclusion at the early stages of development [21]. 
Although there is little research on the education of the medical device industry, an approach 
to HE teaching in practice could benefit from developing collaborations between basic and 
clinical researchers from academic institutions on the one hand, with engineers and scientists 
from the research divisions of device and pharmaceutical companies on the other. Such links 
have been encouraged by the European Society of Cardiology [22] as a way of devising 
legitimate and ethical collaborations between healthcare providers, academic institutions, 
professional associations, charitable foundations, and industry to support continuing medical 
education and facilitate some of the best and most innovative research ideas. However, 
indicative of the ever-increasing range of stakeholders involved in health research, there is 
need for closer examination of diverse groups involved in this process to understand the best 
way to meet their various needs. 
This study points to the need for sustained effort in education of HE so that its principles, and 
the benefits it can deliver, are at the finger-tips of industry when they are preparing their 
evidence. This would allow continued impact of cost-effectiveness in its position of 
supporting healthcare decision makers, particularly in terms of its role for informing technical 
issues around clinical policies [23]. Whilst there have been guidelines developed for 
performing health economic evaluations [24,25], their contribution to decision-making is 
through definition of a minimum methodology to be applied when forming or reviewing an 
economic evaluation. Although this provides support to align expectations of SMEs and 
healthcare providers regarding the construction of economic evaluations, the process of 
deciding whether to adopt an innovation is not prescribed. A similar issue extends out more 
widely into HTA, where the structures, processes and mechanisms by which technology 
coverage decisions can and should be made in healthcare have also been highlighted as 
requiring further research [26]. For HE, there is scope to explore providers‟ decision making, 
and particularly to gauge the importance of economic evaluation within this, which could in 
turn impact on the uptake, construction, and presentation of health economic evaluations by 
SMEs. 
The participants discussed in this paper had attended a workshop hosted by those conducting 
the research which aimed to provide information on both health economics and user needs. 
Whilst it is acknowledged that the sampling strategy may have impacted the research through 
a selection bias, the researchers emphasised confidentiality to participants and, given the 
scarcity of published industry views in this area, were keen to use the collection of workshops 
as a means of interacting with industry for this research. Additionally, an interest in HE may 
have been a cause for participants to register for the workshop, and the training provided in 
HE during the workshop may have helped participants realise its importance. Future research 
could consider alternative approaches to access SMEs, either through targeted interviews or a 
broad survey of trade association memberships. There is scope for more research in the area 
to document the extent of need for HE education in industry, through both increasing the 
sample sizes involved, and by generating comparisons with other company types within the 
medical device sector. 
Conclusion 
This study points to the need for further research into the education requirements of SMEs in 
the area of Health Technology Assessment and also for investigation into how SMEs engage 
with existing HTA processes as required by assessors such as NICE. Furthermore, tools to 
support economic evaluation are of interest to the medical devices industry. It is hoped that 
the findings presented will generate support in bridging the gap between increasing demands 
for health economics evidence by policy makers and the delivery of responsive information 
and self-evaluation of cost-effectiveness of products by SMEs in the medical device sector. 
Competing interests 
The author(s) declare that they have no competing interests. 
Authors' contributions 
MC and JM were involved in the design of the questionnaire and data collection. MC and 
MA performed statistical analysis of the data and prepared the first and subsequent drafts. 
SM was involved in refining the drafts and guiding the study development. All authors read 
and approved the final manuscript. 
References 
1. Donaldson C: Credit Crunch Health Care: How Economics Can Save Our Publicly-funded 
Health Services. Bristol, UK: The Policy Press; 2011. 
2. Kristensen FB, Gerhardus A: Health technology assessments: what do differing 
conclusions tell us? BMJ 2010, 341:c5236. 
3. Eucomed: Joint Healthcare Industry Paper: The value of industry involvement in HTA. 
2011 Position Paper. 
http://www.eucomed.org/uploads/Modules/Publications/111205_final_the_value_of_industry
_involvement_in_hta_241111.pdf. 
4. Hartz S, John J: Public health policy decisions on medical innovations: what role can 
early economic evaluation play? Health Policy 2009, 89(2):184–192. 
5. Healthcare Industries Task Force: Innovation for health: Making a difference. Report of 
the Strategic Implementation Group (SIG). 2007. http://www.dh.gov.uk/ab/HITF/index.htm. 
6. Campbell B: The NICE Medical Technologies Advisory Committee and medical 
technologies guidance. Heart 2011, 97:674–675. 
7. Nellesen D, Birnbaum HG, Greenberg PE: Perspectives on Comparative Effectiveness 
Research: Views from Diverse Constituencies. Pharmacoeconomics 2010, 28(10):789–
798. 
8. Sorenson C, Tarricone R, Siebert M, Drummond M: Applying health economics for 
policy decision making: do devices differ from drugs? Europace 2011, 13:ii54–ii58. 
9. Tarricone R, Drummond M: Challenges in the clinical and economic evaluation of 
medical devices: The case of transcatheter aortic valve implantation. Journal of Medical 
Marketing: Device, Diagnostic and Pharmaceutical Marketing 2011, 11(3):221–229. 
10. Drummond MF, Griffin A, Tarricone R: Economic evaluation for devices and drugs. 
Same or different? Value Health 2009, 12:402–404. 
11. Ubel PA, Loewenstein G, Jepson C: Whose quality of life? A commentary exploring 
discrepancies between health state evaluations of patients and the general public. Qual 
Life Res 2003, 12(6):599–607. 
12. Cosh E, Girling A, Lilford R, McAteer H, Young T: Investing in new medical 
technologies: A decision framework. Journal of Commercial Biotechnology 2007, 
13(4):263–271. 
13. Campbell B: How to judge the value of innovation. BMJ 2012, 344:e1457. 
14. Martin J, Norris B, Murphy E, Crowe J: Design for patient safety: User testing in the 
Development of medical devices. London: NHS National Patient Safety Agency; 2010. 
15. Craven M, Morgan S, Crowe J, Lu B: Deploying a spreadsheet tool for early economic 
value assessment of medical device innovations with healthcare decision makers. Journal 
of Management & Marketing in Healthcare 2009, 2(3):278–292. 
16. Money AG, Barnett J, Kuljis J, Craven MP, Martin JL, Young T: The Role of the User 
within the Medical Device Design and Development Process: Medical Device 
Manufacturers' Perspectives. BMC Med Inform Decis Mak 2011, 11:15. 
17. Phillips C: What is a QALY? Newmarket, UK: Hayward Medical Communications; 2009. 
18. World Health Organisation: Health technology assessment of medical devices. WHO 
Medical device technical series. Geneva: World Health Organization; 2011. 
19. Corabian P, Hailey D, Harstall C, Juzwishin D, Moga C: Mentoring a developing health 
technology assessment initiative in Romania: an example for countries with limited 
experience of assessing health technology. Int J Technol Assess Health Care 2005, 21:522–
525. 
20. Craven MP, Allsop M: The Economic Value of Innovation. European Medical Device 
Technology 2011, 2:3. 
21. Vallejo-Torres L, Steuten LM, Buxton MJ, Girling AJ, Lilford RJ, Young T: Integrating 
health economics modeling in the product development cycle of medical devices: a 
Bayesian approach. Int J Technol Assess Health Care 2008, 24(4):459–464. 
22. Board ESC: Relations between professional medical associations and the health-care 
industry, concerning scientific communication and continuing medical education: a 
Policy Statement from the European Society of Cardiology. Eur Heart J 2011, 33(5):666–
674. 
23. Kuruvilla S, Mays N, Pleasant A, Walt G: Describing the impact of health research: a 
Research Impact Framework. BMC Health Serv Res 2006, 6:134. 
24. Goetghebeur MM, Rindress D: Towards a European consensus on conducting and 
reporting health economic evaluations–a report from the ISPOR Inaugural European 
Conference. Value Health 1999, 2(4):281–287. 
25. National Institute for Health and Clinical Excellence: The guidelines manual. London: 
National Institute for Health and Clinical Excellence; 2012. 
26. Williams I, McIver S, Moore D, Bryan S: The use of economic evaluations in NHS 
decision-making: a review and empirical investigation. Health Technol Assess 2008, 
12(7):1–175. 
Figure 1
